Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis

Pancreatitis, Acute Clinical Trial

Official title:

Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03740685
• Other study ID #: CHCPWDTM
• Status: Not yet recruiting
• Start date: November 9, 2018
• Est. completion date: October 8, 2019

Study information

• Verified date: November 2018
• Source: Assiut University
• Contact: mahmoud Abd Elhamed, principal participant
• Phone: 01017141345
• Email: mahmoudsisi100[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

changes in high sensitive C reactive protien with different treatment modalities in acute pancreatitis

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: October 8, 2019
• Est. primary completion date: November 9, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age>=18 years

• Diagnosis of acute pancreatitis confirmed by at least 2 of the following:

1. Typical epigastric abdominal pain

2. Elevation amylase/lipase >3 times upper limit normal and/or

3. Confirmatory findings on cross-sectional imaging

4. Enrollment within 8 hours of presentation

Exclusion Criteria:

• Class II or greater NYHA heart failure

• Oxygen dependent COPD

• Chronic kidney disease>stage 2

• Existing necrosis on abdominal CT

• Organ dysfunction prior to enrollment

• Sepsis

• Acute respiratory distress syndrome

• Malignancy not in remission for at least 5 years

• Active drug use

• Known allergy to dexamethasone

• Altered mental status

• Insulin-requiring diabetes

• Abdominal surgery within 60days

Related Conditions & MeSH terms

• Pancreatitis
• Pancreatitis, Acute

Intervention

Diagnostic Test:
• High sesitive C reactive protien
High sesitive C reactive protien will be evaluated at admission time and after 36 hours

Locations

Country	Name	City	State
Egypt	Assiut University	Assuit

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	High sesitive C reactive protien	Level of High sesitive C reactive protien expected to be changed with different lines of treatment and will be compaered	72hours
Primary	Serum Amylase	Level of Serum Amylase expected to be changed with different lines of treatment and will be compaered	72hours
Primary	Serum Lipase	Level of Serum Lipase expected to be changed with different lines of treatment and will be compaered	72hours